Here is the most comprehensive review and analysis of the quarterly results of the 10 best pharmaceutical companies. This series provide you with a regular performance update of the major pharmaceutical and biotechnology players.
JOHNSON AND JOHNSON
Product sales Q3 2017: $19,650 million
Product sales 9months ending 2017: $56,255 million
Johnson & Johnson reported sales of $19.7 billion for the third quarter of 2017, which is a significant increase of 10.3% as compared to the third quarter of 2016. Sales of consumer products increased by 2.9% while pharmaceutical sales increased by 15.4%. The main driver of this sales growth are DARZALEX®, IMBRUVICA®, STELARA®, XARELTO® and INVEGA® SUSTENNA®/XEPLION®/TRINZA®. The remarkable sales performance has also been attributed to the recent acquisition of Actelion Ltd which contributed to about 7.9% of the sales growth.
“Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe.”
Johnson and Johnson in the third quarter got an approval by the FDA for an additional indication for IMBRUVICA®. The European Commission granted approval for SYMTUZA® for the treatment of HIV. Other advancement in the pipeline include submission of NDAs for Apalutamide and ZYTIGA® in combination with prednisone.
Product sales Q3 2017: CHF 13,090 million
Product sales 9months ending 2017: CHF 39,434 million
The Swiss pharmaceutical company has reported impressive growth and achievements in this third quarter. Group sales of the company in the last 9 months of 2017 sums up to CHF 39,434 million. Pharmaceutical division made a sum of CHF 30,636 million. Key brands contributing to increased sales are the recently launched brands, Ocruvus, Tecentriq and Alencasa. These three brands contributed a total of CHF 0.9 billion total sales. Other top selling brands are Herceptin, Mab Thera/Rituxan, Avastin and Perjeta.
Regulatory milestones achieved in the third quarter include; EC approval of Tecentriq, Gazyvaro and RoActemra. The FDA also approved Actemra in August for the treatment of cytokine release syndrome (CRS). Alecensa was approved by the European Union’s Committee for Medicinal Products for Human Use (CHMP) for the first line treatment of adults with an anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC. Advancement were also made with ongoing clinical trials. Roche announced results of Murcmo and Alur study in the third quarter
Product sales Q3 2017: $13,168
Product sales 9months ending 2017: $38,843 million
The third quarter sales performance of Pfizer is looking solid with a revenue of $13.168 million which is a 1% increase from the same period of 2016. Key brands driving revenue growth are Ibrance, Xtandi and Xeljanz. Pfizer showcased a 4% revenue growth from key brands Ibrance, Eliquis, Xeljance and the newly acquired Xtandi.
Pfizer received good news this quarter with three significant approvals. FDA approved Bespona and Mylotarg for acute lymphoblastic leukaemia (ALL). Bavencio received European Commission approval for treating adults with metastatic merkel cell carcinoma. Pfizer also announced the completion of two pivotal trials for Xtandi and Trastuzumab.
Product sales Q3 2017: $12,413million
Product sales 9months ending 2017: $36,194million
The net sales in the third quarter of 2017 came to $12.4 billion led particularly by Cosentyx, Entresto, Promacta/Revolade, Tasigna, Tafinlar + Mekinist, Jakavi, and Kisqali. Novartis net sales grew by 2% when compared to its net sales in 2016.
Novartis has a very competitive and robust pipeline of novel therapeutics to treat diseases like cancer and cardiovascular diseases. Recent approvals include: Kymriah for B-cell ALL; Kisqali for breast cancer, Rydapt for Acute myeloid leukemia and Alcon Clareon AutonoMe IOL. With the approval of Kymriah in the third quarter, Novartis became the first company to commercialize a CAR-T therapy. Significant advancements have also been made in ongoing trials up to regulatory submissions and fillings.
Product sales Q3 2017: € 9,053 million
Product sales 9months ending 2017: € 26,364 million
In the third quarter of 2017, the net sales amounted to €9,053. Sanofi showcased a slight sales increase by 0.3% from 2016 Q3. In the 9 months ending 2017, total sales amounted to € 26,364, a positive 5.7% change from 2016 reported numbers. Higher sales volume come from pharmaceuticals but however sales have increased remarkably by 15.2% with vaccines.
Sanofi’s pipeline include new molecular entities for immune-inflammation, neurologic disorders, oncology, rare diseases, diabetes, Cardiovascular diseases, infectious diseases and vaccines. Late pipeline progress of the third quarter include two new registrations of VaxiGrip® Quadrivalent inactivated influenza vaccine and PR5i DTP-HepB-Polio-Hib Pediatric hexavalent vaccine. Sanofi is also advancing 11 candidates in Phase III studies and a total of 31 candidates in either Phase I or Phase II studies.
Product sales Q3 2017: $10,325 million
Product sales 9months ending 2017: $40.0 t0 $40.5 billion
During the third quarter the worldwide sales reached $10.3 Billion, a 2% decrease from the same time last year. Pharmaceutical sales in particular decreased by 3% giving a cumulated sales sum of $9.2 billion. The reduction in sales was accrued to the borrowing from the U.S. Centers for Disease Control and Prevention Pediatric Vaccine Stockpile of GARDASIL 9 worth $240 million. Other reasons for decline in sales is the loss of market exclusivity for several products. “Our performance in the third quarter demonstrates the strength of our underlying business, with growth from key product launches, good global demand for vaccines, as well as strength from our Animal Health business,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “We will continue augmenting our pipeline through value-creating business development like our oncology collaboration with AstraZeneca to address unmet medical need and drive future growth.”
Key pipeline highlights include the FDA approvals of KEYTRUDA and Lynparza for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and ovarian cancer respectively. Recently, Merck also entered into an oncology collaboration with AstraZeneca to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib).
Product sales Q3 2017: $6,995 million
Product sales 9months ending 2017: $20,477 million
The worldwide net revenues of AbbVie in the third quarter of 2017 was $6.995 billion. The major drivers of sales were HUMIRA and IMBRUVICA. HUMIRA sales ($4.701 Billion) increased globally by 15.8% and the global sales of IMBRUVICA ($688 million) increased by 37.3%. In the U.S., HUMIRA sales grew 19.1 percent in the quarter. Internationally, HUMIRA sales grew 6.8 percent, excluding a 2.9 percent favorable impact from foreign exchange. IMBRUVICA net revenues were, with U.S. sales of $574 million and international profit sharing of $114 million for the quarter, reflecting growth of 37.3 percent.
The company has made significant progress in its pipeline during the third quarter. “We are pleased with the significant progress we have made with our strategic priorities, including the recent settlement of our HUMIRA patent disputes with Amgen, and the significant advancement with our late-stage pipeline of innovative products,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “This quarter we achieved a number of milestones, including promising data from several pivotal studies, regulatory approvals for MAVYRET and the U.S. regulatory submission and priority review designation for elagolix. We remain confident in our ability to continue to successfully execute on our long-term strategy and fuel sustainable industry-leading performance.” AbbVie announced top line data and results for late stage development candidates, risankizumab and upadacitinib, in Phase III trials. AbbVie also obtained FDA approval for IMBRUVICA (ibrutinib) as a treatment for adult patients with chronic graft-versus-host-disease (cGVHD).
Product sales Q3 2017: $6,402million
Product sales 9months ending 2017: $19,825million
The financial report of the third quarter reveals that Gilead made a total of $6.4 billion in the last three months. Compared to the $7.4billion reported in the same period in 2016, Gilead has experienced some decline in sales. Drop in sales is reported across all key regional divisions. Despite the decreasing sales, increase in sales of HIV and HBV medicines remains constant particular with these brands Genvoya®, Descovy® and Odefsey®. The financial report of Q3 2017 explains that decline in sales of key brands like Harvoni and Sovaldi across all major markets is partially due to the introduction and sales of Epclusa which was approved in the United States and Europe in June and July 2016, respectively and Vosevi which was approved in the United States and Europe in July 2017.
Gilead has a number of new drugs awaiting approvals from the FDA and other regulatory bodies. Vosevi has been approved for treatment of HCV and Epclusa now has an expanded indication. Two late stage clinical trials are ongoing for a new HIV treatment.
Product sales Q3 2017: $5,453 million
Product sales 9months ending 2017: $16,226 million
Amgen’s product sales in the third quarter of 2017 amounted to $5,453 million, a 1% decline from third quarter sales in 2016. Driving sales in the US were Enbrel, Neulasta and Sensipar/Mimpara. Solid sales growth was reported in recently launched products like Prolia, Repatha and Kyprolis which offset a decline in sales of mature brands.
Advancements in the research and development pipeline include the FDA review of Prolia for the treatment of glucocorticoid-induced osteoporosis and the phase 3 post marketing requirement study of Aransep. Amgen is also advancing its asthma program to phase 3 in collaboration with AstraZeneca. Other early stage clinical developments are the phase 1 studies of AMG 596, AMG 673and AMG 701.
Product sales Q3 2017: $6,232 million
Product sales 9months ending 2017: $16,688 million
According to the recent financial report, AstraZeneca delivered a strong third quarter. Product sales came to $16.7 billion, a 3% bump in sales from last year’s third quarterly sales. Oncology brands showcase a 22% growth in general led by major drivers: Zoladex, Iressa, Faslodex, and Tagrisso. New cardiovascular treatments like Brilinta, Forxiga and Respiratory diseases treatments like Pulmicort and Symbicort also drove sales growth in 2017.
AstraZeneca has a robust pipeline and in the third quarter Astra Zeneca has gotten a number of approvals for new treatments. Other late stage pipeline updates are the phase III trials of Moxetumomab pasudotox, Duaklir and tralokinumab. Astra Zeneca has a total of 11 new potential medicines in Phase III/under registration ahead of busy news flow.
Sources: Annual reports, SEC filings, Press releases, Company websitesBest Pharmaceutical Companies – Quarterly Analysis – Q3 2017last edit: 2018-01-17T17:13:06+00:00da